The American Society of Clinical Oncology annual meeting kicks off today in Chicago, with highly anticipated presentations ...

As evidenced by this week’s buyouts by J&J and Merck, Big Pharma appears to have found a sweet spot favoring smaller deals ...

Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for ...

Regeneron and Sanofi’s Dupixent will have to wait until September 2024 for the FDA to decide whether to expand the drug’s ...

Novartis’ Scemblix posted stronger results with fewer discontinuation rates than both its own Gleevec and a stronger ...

Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two ...

Additional analyses from BridgeBio Pharma’s late-stage study show the oral drug candidate’s improved clinical outcomes in ...

As BioNTech struggles to find its footing in a post-pandemic world, the biotech has secured $145 million from the Coalition ...

Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients ...

Despite Biohaven’s bispecific protein degrader cutting autoantibody IgG levels by up to 37% in an early-stage study, ...

The American Society of Clinical Oncology (ASCO)’s annual meeting kicks off Friday in Chicago, with more than 5,000 abstracts ...

Gilead Sciences announced on Thursday that its antibody-drug conjugate Trodelvy failed to reach the primary endpoint in a ...